TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19966175

Group type: EXPERIMENTAL
Intervention: Trimetazidine (35 mg twice daily)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional therapy alone (Control)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Trimetazidine (in patients with prolonged baseline QTc >440 ms)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Trimetazidine (in patients with normal baseline QTc)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Trimetazidine
Number of subjects: 42
Study: 17593236

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg once daily
Number of subjects: 441

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 441
Study: 15800664

Group type: EXPERIMENTAL
Intervention: Candesartan-based antihypertensive treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 11916549

Group type: COMPARATOR
Intervention: Conventional fractionation (CF) with 70 Gy in 7 weeks, 2 Gy per fraction, daily dose of 6 mg/m² cisplatin
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Modified fractionation (MFD) with three fractions of 1.6 Gy per day, daily dose of 10 mg/m² cisplatin
Number of subjects: 53
Study: 9577904

Group type: EXPERIMENTAL
Intervention: Erythromycin 50 mg i.v.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Erythromycin 200 mg i.v.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Erythromycin 500 mg i.v.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 18
Study: 7897458

Group type: EXPERIMENTAL
Intervention: New antidepressant drugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Older alternatives
Number of subjects: 0
Study: 2678308

Group type: EXPERIMENTAL
Intervention: Captopril (CPT) 50 mg + hydrochlorothiazide (HCTZ) 15 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: HCTZ 25 mg alone
Number of subjects: 30
Study: 345489

Group type: EXPERIMENTAL
Intervention: Single dose of LH-RH
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple doses of LH-RH
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LH-RH in combination with human menopausal gonadotrophins (HMG)
Number of subjects: 0
Study: 31062282

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 72

Group type: COMPARATOR
Intervention: Cathodal tDCS
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 72
Study: 27981366

Group type: EXPERIMENTAL
Intervention: FEC 75 or FEC 100
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Taxotere
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total sample during all cycles
Number of subjects: 0
Study: 25670361

Group type: EXPERIMENTAL
Intervention: 100 g of almonds daily for 4 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Therapeutic Lifestyle Changes Diet counseling (control)
Number of subjects: 48
Study: 23302220

Group type: EXPERIMENTAL
Intervention: Mesalazine (2g granules taken up to twice a day for 12 weeks)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo granule formulation
Number of subjects: 108
Study: 21530092

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy/Motivational Enhancement Therapy (CBT/MET)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naturalistic treatment (Control)
Number of subjects: 0
Study: 19233049

Group type: EXPERIMENTAL
Intervention: Methotrexate and other disease-modifying anti-rheumatic drugs (DMARDs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed therapy
Number of subjects: 0
Study: 16676337

Group type: EXPERIMENTAL
Intervention: Enrollment rate
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Retention rate
Number of subjects: 429
Study: 12638400

Group type: EXPERIMENTAL
Intervention: Ketoprofen 75 mg qid for 3 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acetaminophen 1000 mg qid for 3 days
Number of subjects: 0
Study: 10832216

Group type: EXPERIMENTAL
Intervention: 5 micrograms plasma-derived hepatitis B vaccine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 10 micrograms plasma-derived hepatitis B vaccine
Number of subjects: 50
Study: 9174299

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nitroprusside
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 20
Study: 8018138

Group type: EXPERIMENTAL
Intervention: Active compression-decompression CPR
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard CPR
Number of subjects: 62
Study: 3942473

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: CT plus active placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: CT plus pharmacotherapy
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Overall treatment response
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Dysfunctional attitudes measure
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Residual depression levels
Number of subjects: 70
Study: 30538078

Group type: EXPERIMENTAL
Intervention: Offensive task
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Defensive task
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Short regime
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Long regime
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Offense-long SSG
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Defense-short SSG
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Post-SSGs
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Offense-short SSG
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Defense-long SSG
Number of subjects: 12
Study: 29132477

Group type: EXPERIMENTAL
Intervention: Ilioinguinal nerve preservation (Group A)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Wide elective division of ilioinguinal nerve (Group B)
Number of subjects: 84
Study: 26071306

Group type: EXPERIMENTAL
Intervention: Electronic feedback and referral to online and telephone services for health risk behaviours.
Number of subjects: 100

Group type: COMPARATOR
Intervention: No intervention (control group).
Number of subjects: 100
Study: 23462477

Group type: EXPERIMENTAL
Intervention: Intervention group (school-based intervention)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 226
Study: 21401682

Group type: EXPERIMENTAL
Intervention: Workshop
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Lecture
Number of subjects: 223

Group type: COMPARATOR
Intervention: Self-Directed Learning (SDL)
Number of subjects: 223
Study: 19682321

Group type: COMPARATOR
Intervention: Ziconotide monotherapy
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ziconotide (in combination with other IT agents)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 17148528

Group type: EXPERIMENTAL
Intervention: Case conferences
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: General practitioner education
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Patient education
Number of subjects: 461
Study: 12753571

Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (1 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Quazepam (15 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (Triazolam)
Number of subjects: 15
Study: 11641942

Group type: EXPERIMENTAL
Intervention: Epifamine (400 mg course dose)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 9232978

Group type: EXPERIMENTAL
Intervention: Walk group
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Run group
Number of subjects: 350
Study: 8425683

Group type: EXPERIMENTAL
Intervention: Actively smoking
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham smoking
Number of subjects: 30
Study: 3595078

Group type: EXPERIMENTAL
Intervention: Dopamine (0.1 microgram min‐1 kg‐1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Dopamine (1 microgram min‐1 kg‐1)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 6
Study: 29258938

Group type: EXPERIMENTAL
Intervention: Neuroendoscopy
Number of subjects: 213

Group type: COMPARATOR
Intervention: Microscopy
Number of subjects: 213
Study: 26439114

Group type: EXPERIMENTAL
Intervention: Structured lifestyle advice program + pelvic floor muscle training (PFMT)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Structured lifestyle advice program
Number of subjects: 109
Study: 25915721

Group type: EXPERIMENTAL
Intervention: Soft splinting
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Manual stretching
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 17
Study: 23731594

Group type: EXPERIMENTAL
Intervention: Systems-level intervention consisting of a menu of evidence-based implementation strategies for increasing colorectal cancer screening.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Implementation outcomes informed by the RE-AIM conceptual framework.
Number of subjects: 16
Study: 22133240

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation cycling (FESC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Passive cycling (PC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Noncycling, electrically stimulated exercise (ES)
Number of subjects: 30
Study: 19745643

Group type: EXPERIMENTAL
Intervention: Fexofenadine (360 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Methylphenidate (20 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 17009343

Group type: EXPERIMENTAL
Intervention: Responses to Stress Questionnaire‐cancer version (RSQ‐CV)
Number of subjects: 232
Study: 15328675

Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray, 2 sprays per nostril twice daily
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray, 2 sprays per nostril twice daily plus fexofenadine, 60 mg twice daily
Number of subjects: 334

Group type: COMPARATOR
Intervention: Placebo (saline) nasal spray and placebo capsules twice daily
Number of subjects: 334
Study: 11177420

Group type: EXPERIMENTAL
Intervention: Restitution training (PeriMa program)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Restitution training (PeriForm)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Restitution training (PeriColor)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Conventional perimetry (experimental group)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo group (fixation training, PeriMa)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo group (fixation training, PeriForm)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo group (fixation training, PeriColor)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Correlation between PeriMa and PeriForm
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Correlation between PeriMa and PeriColor
Number of subjects: 32
Study: 9301445

Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) 100 mg/m2 combined with 5-fluorouracil (5-FU) 1000 mg/m2 continuous infusion from days 1-5 (Arm A)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Cisplatin (CDDP) alone (Arm B)
Number of subjects: 88
Study: 7687708

Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg once daily
Number of subjects: 114
Study: 2442513

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 29505101

Group type: EXPERIMENTAL
Intervention: 50 mg JNJ-54861911 once daily for 7 days
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 150 mg JNJ-54861911 once daily for 7 days
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 400 mg moxifloxacin
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 90 mg JNJ-54861911 once daily for 7 days
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 150 mg JNJ-54861911
Number of subjects: 64
Study: 27807925

Group type: EXPERIMENTAL
Intervention: Topiramate 75 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 25010303

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg plus sildenafil 50 mg
Number of subjects: 101

Group type: COMPARATOR
Intervention: Tamsulosin 0.4 mg plus placebo
Number of subjects: 101
Study: 23516873

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 20
Study: 20822543

Group type: EXPERIMENTAL
Intervention: Multi-component physical activity intervention delivered by childcare service staff
Number of subjects: 300

Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 300
Study: 18367288

Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy (TRT) with a planned dose of 50Gy in 2Gy daily fractions, initiated with the fourth chemotherapy cycle.
Number of subjects: 267

Group type: COMPARATOR
Intervention: Control group receiving standard chemo-radiotherapy without specified intervention details.
Number of subjects: 267
Study: 22036029

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg body weight
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg body weight
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg body weight
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 30 mg advantame/day (split into 3 doses per day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 16088265

Group type: EXPERIMENTAL
Intervention: Mind-body therapy (structured 60-hour training program over 10 weeks including stress management training, moderate exercise, Mediterranean diet, behavioral techniques and self-care strategies)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mind-body therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual-care waiting control group
Number of subjects: 30
Study: 12017349

Group type: EXPERIMENTAL
Intervention: Verteporfin 3 to 20 mg/m2 of body surface area infused over 1.5 to 45 minutes
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Verteporfin
Number of subjects: 69
Study: 10874370

Group type: EXPERIMENTAL
Intervention: 3 days oral chloroquine plus single dose sulphadoxin/pyrimethamine (CQ + SP)
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: 3 days oral quinine plus single dose sulphadoxin/pyrimethamine (Q3 + SP)
Number of subjects: 784
Study: 8573234

Group type: EXPERIMENTAL
Intervention: Rooming-in (extended and early contact)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Minimal contact (contact only during feedings)
Number of subjects: 31
Study: 2676668

Group type: COMPARATOR
Intervention: Oral glucose tolerance test
Number of subjects: 99

Group type: COMPARATOR
Intervention: Meal tolerance test
Number of subjects: 99
Study: 134722

Group type: EXPERIMENTAL
Intervention: Ipratropiumbromide by inhalation (max dose 2.4 mg)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Atropine sulphate by inhalation (1.6 mg and 2.4 mg)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Ipratropiumbromide by i.v. injection (max dose 0.28 mg)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Ipratropiumbromide by i.v. injection (0.28 mg)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Atropine sulphate by inhalation
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Ipratropiumbromide by inhalation
Number of subjects: 43
Study: 11454180

Group type: EXPERIMENTAL
Intervention: IFN 4.5 MU daily plus amantadine 200 mg/day for 4 weeks and then IFN 6 MU thrice weekly plus amantadine 200 mg/day for an additional 5 months (group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: IFN alone at the same dosage and duration (group B)
Number of subjects: 40
Study: 30768419

Group type: EXPERIMENTAL
Intervention: Chicago Parent Program (CPP)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Parent-Child Interaction Therapy (PCIT)
Number of subjects: 158
Study: 29452812

Group type: EXPERIMENTAL
Intervention: Upper body warming
Number of subjects: 123
Study: 26964861

Group type: EXPERIMENTAL
Intervention: Intraoperative retractor sponge
Number of subjects: 188

Group type: COMPARATOR
Intervention: Standard treatment (Trendelenburg position)
Number of subjects: 188
Study: 24617731

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion with bone marrow‐derived mononuclear cells (BMMCs)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion with peripheral blood‐derived mononuclear cells (PBMCs)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Standard therapy (control group)
Number of subjects: 152
Study: 22137804

Group type: EXPERIMENTAL
Intervention: Liberal blood glucose strategy (121‐180 mg/dL)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Strict blood glucose strategy (90‐120 mg/dL)
Number of subjects: 189
Study: 20373139

Group type: EXPERIMENTAL
Intervention: HIV prevention intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 120
Study: 17365165

Group type: EXPERIMENTAL
Intervention: Spirituality intervention in persons living with HIV disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spirituality intervention in healthy adults
Number of subjects: 0
Study: 15972045

Group type: EXPERIMENTAL
Intervention: Botulinum toxin (Botox)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sphincterotomy
Number of subjects: 38
Study: 12628944

Group type: EXPERIMENTAL
Intervention: Roxithromycin (300 mg daily for 6 weeks)
Number of subjects: 872

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: Roxithromycin
Number of subjects: 872
Study: 11783213

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine mixture (CHMM)
Number of subjects: 0
Study: 9117472

Group type: EXPERIMENTAL
Intervention: Integrated service agency program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual services (comparison group)
Number of subjects: 0
Study: 1751351

Group type: EXPERIMENTAL
Intervention: 2% plain lignocaine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Lignocaine with adrenaline 1:200,000
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sodium metabisulphite in adrenalized lignocaine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Neutralization of acidic 0.5% lignocaine (pH 4.7)
Number of subjects: 32

Group type: COMPARATOR
Intervention: 0.5% plain lignocaine
Number of subjects: 32
Study: 6753706

Group type: EXPERIMENTAL
Intervention: Dipyridamole-naproxen
Number of subjects: 65

Group type: COMPARATOR
Intervention: Low-dose heparin
Number of subjects: 65
Study: 30101576

Group type: EXPERIMENTAL
Intervention: Improved nutrition with infant and young child feeding messages and lipid-based nutrient supplementation (N)
Number of subjects: 4718

Group type: EXPERIMENTAL
Intervention: N+WSH (Nutrition + Water, Sanitation, and Handwashing)
Number of subjects: 4718

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 4718

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplementation
Number of subjects: 4718
Study: 29330071

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (300 U into ankle plantar flexors; ≤100 U optional lower limb muscles)
Number of subjects: 468

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA/onabotulinumtoxinA
Number of subjects: 468

Group type: COMPARATOR
Intervention: Placebo/onabotulinumtoxinA
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 468
Study: 24802769

Group type: EXPERIMENTAL
Intervention: Adaptive compression therapy (ACT) system
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional four-layer bandage system
Number of subjects: 90
Study: 25191981

Group type: EXPERIMENTAL
Intervention: ATP infusion (100 μg/kg/min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Midazolam alone
Number of subjects: 10
Study: 22230722

Group type: EXPERIMENTAL
Intervention: NaF
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Amine fluoride
Number of subjects: 8
Study: 19058232

Group type: EXPERIMENTAL
Intervention: 5-aminosalicylate (5-ASA)
Number of subjects: 1048

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1048
Study: 17217450

Group type: EXPERIMENTAL
Intervention: NK-1 receptor antagonist (NK-1RA)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 15896583

Group type: EXPERIMENTAL
Intervention: Mild hemodilution group (group A, N=15) with hematocrit level of 32%
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Moderate hemodilution group (group B, N=15) with hematocrit level of 24%
Number of subjects: 30
Study: 12135828

Group type: EXPERIMENTAL
Intervention: Insulin intake regulation methods based on experience-based knowledge
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Qualitative insights from semi-structured interviews
Number of subjects: 10
Study: 9884136

Group type: COMPARATOR
Intervention: Placebo beverages (1 ml alcohol)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.35 g/kg of alcohol beverages
Number of subjects: 20
Study: 7481209

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 1229

Group type: COMPARATOR
Intervention: No adjuvant systemic therapy (control)
Number of subjects: 1229
Study: 2650582

Group type: EXPERIMENTAL
Intervention: Quinapril (20-80 mg/day)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Captopril (50-200 mg/day)
Number of subjects: 172
Study: 352484

Group type: EXPERIMENTAL
Intervention: Diazepam (0.15 mg/kg intramuscularly for premedication and 0.3 mg/sec intravenously for induction)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Diazepam (as an induction agent)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Diazepam (premedication and induction)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Diazepam (premedication)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Meperidine (1 mg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Thiopentone (2.5 mg/sec)
Number of subjects: 40
Study: 30368628

Group type: EXPERIMENTAL
Intervention: An Individualized Mental Health Intervention for Children with ASD (AIM HI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: AIM HI
Number of subjects: 0
Study: 28503725

Group type: EXPERIMENTAL
Intervention: Non-extraction treatment with fixed appliances for a mean period of 2.46 years
Number of subjects: 60

Group type: COMPARATOR
Intervention: Extraction treatment with fixed appliances for a mean period of 2.49 years
Number of subjects: 60